Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALAXI phase 2/3 study of guselkumab versus placebo and ustekinumab in moderately to severely active Crohn's disease
NL-OMON52566Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guselkumab in Crohn's disease and inflammatory bowel disease (IBD), sponsored by Janssen Pharmaceutical. Primary endpoints: Change from baseline in Crohn's Disease Activity Index score at Week 12, Clinical remission at Week 12 and 1 more. Started Oct 2019; status: recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON52566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52566.